Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGIAS: Trabectedin and Low-dose Radiation in Advanced Sarcomas
NCT05131386Phase 2Unknown
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- May 2021
- Primary completion
- Jul 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin in soft tissue sarcoma (STS), osteosarcoma (OS), chondrosarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS), sponsored by Spanish Group for Research on Sarcoma. Status: unknown.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)chondrosarcomaEwing sarcomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT05131386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131386.